Low BDNF concentrations in schizophrenia may be caused by non-linearity of BDNF correlation with age caused by its interaction with sex by Maja Vilibić et al.
Low BDNF concentrations in schizophrenia may 
be caused by non-linearity of BDNF correlation 
with age caused by its interaction with sex
Maja Vilibić1, Karolina Novački2, Nada Vrkić2,3, Dalibor Karlović1,4
1Department of Psychiatry, University Hospital Center Sestre milosrdnice, Zagreb, Croa-
tia, 2Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and 
Biochemistry, University of Zagreb, Zagreb, Croatia, 3Department of Clinical Chemistry, 
University Hospital Center Sestre milosrdnice, Zagreb, Croatia, 4 Catholic University of 
Croatia, Zagreb, Croatia
Original paper
Alcoholism and Psychiatry Research 2018;54:21-32
DOI: 10.20471/may.2018.54.01.02
Received February 21, 2018, accepted after revision March 12, 2018  
Correspondence to: Maja Vilibić
Department of Psychiatry, Sestre milosrdnice University Hospital 
Center, Vinogradska 29, Zagreb, Croatia
Phone: +385 91 553 7700
E-mail: maja.vilibic@gmail.com
Copyright © 2018 KBCSM, Zagreb
e-mail: alcoholism.kbcsm@gmail.com • www.http://apr.kbcsm.hr
Abstract - Considerable inconsistencies exist between results of the studies on brain-derived neurotrophic 
factor (BDNF) peripheral concentrations and schizophrenia (SCH). The objective of our study was to check 
whether these inconsistencies may be explained by confounding effects of age and sex. In this cross-sectional 
study performed during 2017 at Department of Psychiatry, University Hospital Center Sestre milosrdnice, Za-
greb, Croatia, we included a sample of 41 patients diagnosed with SCH. The main outcome was BDNF serum 
concentrations. We have detected a significant cross-over interaction of sex and age on BDNF concentration 
(p=0.017). In male patients BNDF concentrations significantly increase with age. In female patients the cor-
relation between age and BDNF was not significant. On this particular sample level, it was negative: aging 
was associated with the decrease of BDNF concentrations in female patients. BDNF concentrations were 
significantly different between female and male patients under the age of 22 years (total of 7% of patients), 
and above the age of 65 (total of 10% of patients). BDNF may be a promising schizophrenia biomarker, but 
different norms should be proposed for the patients of different age and sex.
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Introduction
In patients with schizophrenia (SCH), 
brain-derived neurotrophic factor (BDNF) 
and nerve growth factor (NGF) concentra-
tions in the cerebrospinal fluid have been re-
duced since the first psychotic episode [1-3]. 
Post-mortem studies have demonstrated re-
duced levels of  BDNF mRNA and proteins 
in the prefrontal cortex [4]. As far as periph-
eral BDNF concentrations are concerned, 
previous studies have shown different results 
depending on the type of  biological sample 
used (serum or plasma), stage of  disease, 
sex, and pharmacotherapy use. Nonetheless, 
most results are in favor of  reduced levels of  
BDNF in serum of  patients with schizophre-
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nia, and some also indicate a clear correla-
tion with negative and catatonic symptoms 
[5]. Val66Met polymorphism of  BDNF gene 
has its effect also in schizophrenia [6]. Nega-
tive influence on protein expression regulates 
signal transmission, synaptic localization of  
BDNF and branching dendrites in the hip-
pocampus [7]. Thus, this single nucleotide 
polymorphism (SNP) is associated with 
worse neurocognitive function, neuroticism 
and introversion in patients with schizophre-
nia [8]. Contrary to most research, Gama et 
al. reported elevated BDNF concentration 
in chronic schizophrenia [9]. The elevated 
BDNF level can be a sign of  clinical im-
provement, and this is accompanied with the 
fact that the patients involved in the research 
have been in a phase of  remission and have 
been suffering from schizophrenia for years. 
Significant neurodegenerative processes may 
be more active at the earlier stage of  the dis-
ease (5-10 years), and such elevated levels of  
BDNF have been found in advanced long-
term schizophrenia or the result of  a dam-
aged tissue reaction, or the chronic stage of  
disease is a period of  reduced metabolic ag-
gression towards the brain. Considering this, 
elevated levels of  BDNF may be the result 
of  the progression of  schizophrenia or the 
consequence of  long-term therapy with anti-
psychotics [9]. For the adequate function of  
neurotrophin, it is not only necessary to in-
crease the level of  BDNF but also to adjust 
the proportion of  functional and shortened 
TrkB receptors [10]. The ratio of  these two 
receptor forms can be a useful indicator of  
the actual functioning of  BDNF. According-
ly, the increase in proportion of  functional 
and reduction in the proportion of  short-
ened, nonfunctional receptor form could 
be the target of  possible future therapeutic 
agent with the aim of  improving BDNF sig-
naling in psychotic patients. Patients with in-
creased functional receptor proportion, re-
spond better to antipsychotic therapy [11]. 
According to the fact that even 50% of  
patients with schizophrenia have depres-
sive symptoms, the relationship between se-
rum biomarkers and depressive symptoms 
in schizophrenia has also been well studied 
[12,13]. Depressive mood in patients with 
schizophrenia is associated with long periods 
of  hospitalization, poor response to therapy, 
poor social and cognitive skills, and high re-
lapse frequency [14]. Given that depression 
and schizophrenia are accompanied with a 
reduction of  BDNF levels, the assumption 
was that their co-occurrence would result in 
even lower levels, but researches showed the 
opposite. Surprisingly, people with more se-
vere depressive symptoms had higher levels 
of  BDNF. The cause of  this was again or 
chronic progression of  the disease stage, or 
high daily dose of  drugs [12]. In conclusion, 
BDNF could be used as a cognitive deficien-
cy biomarker and as a predictor of  clinical 
prognosis in schizophrenia, but the interpre-
tation of  results must take into account the 
stage of  disease, therapy, and other factors 
affecting its concentration. The objective of  
our study was to check whether the inconsis-
tencies in studies’ findings may be explained 
by confounding effects of  age, sex or treat-
ment with antipsychotics.
Subjects and Methods
Study design and subjects
This cross-sectional study was conducted 
during 2017 at the Department of  Psychiatry 
of  University Hospital Center Sestre milosrd-
nice, Zagreb, Croatia. Ethics Committee of  
University Hospital Center Sestre milosrd-
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nice approved the study protocol, and we 
obtained the informed consents from all pa-
tients enrolled. The study was conducted in 
accordance with World Medical Association 
Declaration of  Helsinki 2013 [15]. 
The targeted population included patients 
diagnosed with SCH (F20), according to 
ICD-10 criteria [16]. Inclusion criteria were: 
confirmed diagnosis of  SCH, both sex, age 
19 to 80 years, treated in tertiary psychiatric 
hospital as inpatients. Exclusion criteria were: 
acute suicide threat, psychoorganic syndrome 
or mental retardation as schizophrenia co-
morbidity, and acute intoxication. 
We chose a consecutive sample of  pa-
tients by the order of  admission to the hospi-
tal. Independent variables were age and sex. 
These data were obtained from the Hospital 
medical records.
Serum BDNF determination
Our outcome was BNDF serum concen-
tration. It was determined by ELISA (Enzyme-
Linked Immunosorbent Assay) method using the 
ready-made reagent kit, in which the reaction 
is based on noncompetitive sandwich princi-
ple. Determination of  BDNF concentration 
was performed at the Department of  Clini-
cal Chemistry of  University Hospital Centre 
Sestre milosrdnice, using the reagent kit of  
LifeSpan BioScineces, Inc., USA.
Statistical analysis
We calculated the needed sample size and 
power analysis before the beginning of  data 
collection. A sample size of  33 produces a 
two-sided 80% confidence interval with a 
width equal to 0,30 when the estimate of  
Pearson’s product-moment correlation is 
r=0,60. Needed sample size was calculat-
ed by PASS 15 Power Analysis and Sample 
Size Software (2017). NCSS, LLC. Kaysville, 
Utah, USA, ncss.com/software/pass.
It was planned in advanced that we will do 
a sensitivity analysis by repeating the calcula-
tion on the file with multiply imputed data 
if  ≥5% were missing. However, this has not 
happened. Therefore the analysis was done 
on the cases with complete data only, and 
the number (proportion) of  missing data 
was reported bellow the tables. In all cases 
the level of  two-tail significance was p<0.05 
with confidence intervals on 95% level. The 
main analysis of  correlation of  age with 
BDNF concentration and moderating effect 
of  sex was performed by Johnson-Neyman 
technique as it was implemented in Andrew 
F. Hayes macro PROCESS. Scatter plot with 
locally weighted regression smoothed trend-
lines of  BDNF on age by sex was plotted in 
MedCalc Statistical Software version 15.6.1 
(MedCalc Software bvba, Ostend, Belgium; 
https://www.medcalc.org; 2015). Statisti-
cal data analysis was performed by NCSS 
11 Statistical Software (2016; NCSS, LLC; 
Kaysville, Utah, USA). 
Results
Total of  61 patients were assessed for 
eligibility (Figure 1). We finally included 41 
patients, (most of  whom were markedly ill, 
73.2%) [17], with the median (IQR) aged 39 
(30-58) years. The overall age range was from 
19 to 80 years (Table 1).
Median (IQR) BDNF concentration was 
31 (21-44) ng/ml, ranging from 4 ng/ml to 
63 ng/ml. We have not found significant nor 
clinically relevant difference in BDNF con-
centrations between female and male patients 
diagnosed with SCH. Crude, unadjusted me-
dian (IQR) BDNF concentration was 32 (21-
45) ng/ml in female, and 29 (21-45) ng/ml 
24
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Table 1. Participants sociodemographic and clinical characteristics
n (%)
Age (years), median (IQR) 39 (30-58)
Sex
 female 28 (68.3)
 male 13 (31.7)
Education
 primary 3 (7.3)
 secondary 29 (70.7)
 university 9 (22.0)
Age at illness 
 onset, median (IQR) 27 (21-32)
Duration of  illness 
 (years), median (IQR) 12 (7-20)
CGI-S
 moderately ill 9 (22.0)
 markedly ill 30 (73.2)
 severely ill 2 (4.8)
Treatment with antipsychotics
 1st generation 8 (19.5)
 2nd generation 33 (80.5)
Antidepressants 0 (0.0)
Benzodiazepines 37 (90.2)
Data are presented as number (percentage) of  participants if  not stated otherwise
Abbreviation: IQR = interquartile range; CGI-S = Clinical global impression severity scale [17]
Figure 1. Psychiatric patients study flow
in male patients (Mann-Whitney test, U=171; 
Z=-0.31; p=0.758). Median (95% CI) BDNF 
concentration adjusted by quantile regression 
for age was 33 (27-39) ng/ml in female and 
32 (24-39) ng/ml in male patients (b=-1.24; 
s.e.=4.80; t=-0.26; p=0.798). Spearman rank 
correlation between BDNF concentration 
and age was ρ=0.10; p=0.548.
We have detected the significant cross-
over interaction of  sex and age on the con-
centrations of  BDNF (Table 2, Figure 2). 
Increase of  coefficient of  determination of  
BDNF by the interaction of  sex and age was 
25
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Table 2. Linear regression of  BDNF on age and sex
b 95% CI se t p
Constant 41.7 (25.8 - 57.6) 7.86 5.31 <0.001
Sex -31.7 (-58.5 - 4.99) 13.20 -2.41 0.021
Age (years) -0.20 (-0.53 - 0.13) 0.16 -1.21 0.235
Interaction of  sex x age 0.78 (0.15 - 1.40) 0.31 2.50 0.017
Abbreviation: b = regression coefficient; CI = confidence interval of  regression coefficient; se = stan-
dard error; t = t-statistic; p = statistical significance
Figure 2. Scatter plot with locally weighted regression smoothed trendlines of  BNDF on age by 
sex (n=28 female, n=13 male); degree of  smoothing, span=100%
26
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R2=0.14; p=0.017. Age was significantly cor-
related with BDNF concentration in male, 
but not in female patients, and the correla-
tions in two different sexes were of  differ-
ent sign (Table 3). Pearson correlation coeffi-
cient between BDNF concentration and age 
was r=0.55, p=0.050 in male, and r= -0.23; 
p=0.239 in female. Using Jonhson-Neyman 
technique we found that BDNF concentra-
tions were significantly different between fe-
male and male patients bellow the age of  22 
years (total of  7% of  patients), and above the 
age of  65 (total of  10% of  patients) (Table 
4).
Discussion
Our study shows the cross-over interac-
tion of  sex and age in BDNF concentration. 
In male patients BNDF concentrations sig-
nificantly increased with age. In female pa-
tients the correlation between age and BDNF 
was not significant. On this particular sample 
level, it was negative: aging was associated 
with the decrease of  BDNF concentrations.
Some previous studies found the sex dif-
ference of  BDNF levels between ones with 
and without metabolic syndrome among pa-
tients with schizophrenia [18]. In male pa-
tients with schizophrenia, those with meta-
bolic syndrome had significantly higher 
serum BDNF levels than those without it. In 
our study in male patients BDNF concentra-
tions significantly increased with age. Elderly 
male patients with schizophrenia could have 
an increased risk or non-diagnosed (not aim 
of  our study) but presented metabolic syn-
drome and consecutively higher BDNF lev-
els. Also, average dosages of  psychopharma-
ceuticals prescribed to our male patients with 
schizophrenia were generally somewhat high-
er than those prescribed to female patients 
with the same disorder and of  the same age, 
and such practice could partially contribute 
to the explanation why BDNF concentration 
significantly increased with age in male pa-
tients. Also, it should be reminded that Ike-
game et al. found that higher level of  meth-
ylation at BDNF promoter I was found in 
patients with schizophrenia compared with 
controls and particularly the methylation dif-
ference was more prominent in male patients 
[19]. Various, probably complementary and 
synergistic mechanisms, not uniformly de-
fined yet, could be expected in the basis of  
found cross-over interaction of  sex and age 
on BDNF concentration.
BDNF serum and plasma reduction was 
demonstrated in patients with schizophrenia 
[20], as well as in many other psychiatric and 
Table 3. Conditional effects of  age on BDNF at different sex
b 95% CI se t p
Age effect by different sex
 female -0.20 (-0.53 - 0.13) 0.16 -1.21 0.235
 male 0.58 (0.04 - 1.11) 0.26 2.19 0.035
Abbreviation: b = regression coefficient; CI = confidence interval of  regression coefficient; se = stan-
dard error; t = t-statistic; p = statistical significance
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Table 4. Conditional effects of  sex on BDNF at different ages
b 95% CI se t p
Age (years)
 19.0 -17.01 (-33.18 - 0.85) 7.98 -2.13 0.040
 22.0 -14.70 (-29.39 - 0.00) 7.25 -2.03 0.050
 22.1 -14.65 (-29.32 - 0.02) 7.24 -2.02 0.050
 25.1 -12.29 (-25.57 - 0.99) 6.55 -1.88 0.069
 28.2 -9.92 (-21.96 - 2.12) 5.94 -1.67 0.103
 31.2 -7.56 (-18.55 - 3.43) 5.43 -1.39 0.172
 34.3 -5.20 (-15.40 - 5.01) 5.04 -1.03 0.309
 37.3 -2.83 (-12.57 - 6.91) 4.81 -0.59 0.559
 40.4 -0.47 (-10.11 - 9.17) 4.76 -0.10 0.922
 43.4 1.89 (-8.02 - 11.81) 4.89 0.39 0.701
 46.5 4.26 (-6.29 - 14.80) 5.20 0.82 0.419
 49.5 6.62 (-4.84 - 18.08) 5.66 1.17 0.249
 52.6 8.98 (-3.62 - 21.59) 6.22 1.44 0.157
 55.6 11.35 (-2.57 - 25.27) 6.87 1.65 0.107
 58.7 13.71 (-1.65 - 29.07) 7.58 1.81 0.079
 61.7 16.07 (-0.83 - 32.98) 8.34 1.93 0.062
 64.8 18.44 (-0.08 - 36.95) 9.14 2.02 0.051
 65.1 18.68 (0.00 - 37.37) 9.22 2.03 0.050
 67.8 20.80 (0.62 - 40.98) 9.96 2.09 0.044
 70.9 23.16 (1.28 - 45.05) 10.80 2.15 0.039
 73.9 25.53 (1.91 - 49.15) 11.66 2.19 0.035
 77.0 27.89 (2.50 - 53.28) 12.53 2.23 0.032
 80.0 30.25 (3.08 - 57.43) 13.41 2.26 0.030
Abbreviation: b = regression coefficient; CI = confidence interval of  regression coefficient; se = 
standard error; t = t-statistic; p = statistical significance
neurodegenerative diseases: depression [21])
and is found in both human serum and plas-
ma. Animal studies have demonstrated that 
stress reduces BDNF expression or activity in 
the hippocampus and that this reduction can 
be prevented by treatment with antidepres-
sant drugs. A similar change in BDNF activ-
ity occurs in the brain of  patients with major 
depression disorder (MDD, bipolar disorder 
[22], Huntington’s disease [23], Alzheimer’s 
disease [24] and autism [25]. This indicates 
that the low level of  BDNF is not specific 
to a particular mental disorder, which could 
limit its use as a specific diagnostic marker. In 
fact, the serum BDNF concentration could 
serve as a marker of  neuropathological sen-
28
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sitivity leading to various disorders. Another 
issue is the question of  how much the BDNF 
concentration in the blood (serum or plasma) 
reflects the brain concentration. Although 
BDNF has been shown to cross the blood-
brain barrier with a high-capacity saturating 
high-capacity transport system in both direc-
tions [26] and despite the positive correlation 
found between serum and cortical levels of  
BDNF [27], as well as between levels in the 
blood and the hippocampus [28], it is still un-
clear to what extent this correlation is correct 
because the remaining tissues in the periphery 
are also the source of  BDNF. In recent years, 
BDNF has been found in the peripheral ner-
vous system as well as other organs, such 
as ovaries, lungs, heart and skeletal muscles 
[29]. In the blood, BDNF is mostly stored in 
platelets but is not synthesized there [30,31]. 
Thus, there is also a difference in BDNF 
levels in serum and plasma. Serum concen-
trations are somewhat higher due to release 
from platelets during clotting. It should be 
noted that platelets store BDNF from dif-
ferent sources, including nerve and endothe-
lial cells, and thus somehow serve to regulate 
homeostasis by storing BDNF for release in 
periods of  increased need [30]. BDNF serum 
levels probably represent an integrated com-
position from different sources and dynam-
ics in changes in these levels does not have to 
be closely related to those in the central ner-
vous system [32]. Trajkovska et al.’s research 
has shown that the concentration of  BDNF 
in full blood is significantly higher in women 
than in men [33], whereas other studies have 
not shown significant differences in sex ei-
ther in plasma or in serum [34-36]. There is a 
possibility that antipsychotic therapy balanc-
es BDNF levels and higher dosages are prob-
ably prescribed to patients with more severe 
symptoms. This is in favor of  the higher lev-
els of  BDNF that have been proven in long-
term patients and in those receiving high 
daily dose of  therapy [9,37]. The interpreta-
tion of  findings from the sample with newly 
diagnosed SCH is further complicated with 
the unknown period of  undetected psycho-
sis. Like many other molecules in the human 
body, aging also decreases BDNF levels. Due 
to the important role of  BDNF in brain de-
velopment and memory, with years learning 
and memory capacity weakens. Nevertheless, 
the correlation between age and BDNF con-
centration was found in this study as in most 
previous ones.
Further studies on a much larger patients’ 
sample are needed to clarify the preliminary 
found interaction between age and sex on 
BDNF levels in patients with schizophrenia.
The first limitation of  our study was that 
we chose a consecutive and not a random 
sample of  patients with schizophrenia. It is 
possible that patients with particular BDNF 
concentration have different seasonal pat-
terns of  presenting at the psychiatric hospi-
tal. We collected the data during spring and 
early summer and this could induce a sample 
error. Secondly, we have not collected the 
data on antipsychotic dosages. Male patients 
require higher dosages [38]. Higher dosages 
may be associated with higher BDNF con-
centrations. If  our samples from the popula-
tion of  male and female patients with schizo-
phrenia had different median antipsychotic 
dosages, the difference in BDNF concen-
tration between female and male patients 
might have been larger after the adjustment 
of  the dosages confounding effect. Thirdly, 
we have not collected data on the adherence. 
If  the BDNF concentrations are associated 
with symptoms severity and pharmacothera-
py, then the adherence to the recommended 
treatment may confound the main results. 
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This potential source of  bias is most likely 
low as we did the study on the sample of  
hospitalized patients. Forth, our results could 
be biased by the storage of  samples. Studies 
have shown that storage of  serum but not 
full blood at -20 °C is associated with signifi-
cant reduction of  BDNF concentration [33]. 
Unreliability contributes to the fact that, for 
the purposes of  this study, samples were col-
lected over a longer period of  time on sev-
eral occasions. Bus et al. recently identified 
eight independent factors affecting BDNF 
concentration: sampling time, sample storage 
time, pre-sampling food consumption, origin 
of  the patient, age, sex, smoking and alcohol 
consumption [39]. 
BDNF may be a promising schizophre-
nia biomarker, but different norms should 
be proposed for the patients of  different age 
and sex.
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Sažetak - Rezultati dosadašnjih istraživanja o perifernoj koncentraciji moždanog neurotrofnog čimbenika 
rasta  (engl. brain derived neurotrophic factor, BDNF) u shizofreniji (SCH) su pokazali određene nedosljed-
nosti. Cilj ovog istraživanja bio je istražiti mogu li ove nedosljednosti biti objašnjene konfundirajućim učincima 
dobi i spola. U ovom presječnom istraživanju, provedenom tijekom 2017 na Klinici za psihijatriju, Kliničkog 
bolničkog centra Sestre milosrdnice, Zagreb, Hrvatska, uključen je uzorak od 41 bolesnika/ispitanika s dijag-
nosticiranom SCH. Glavni ishod bile su koncentracije BDNF-a u serumu. Nađena je značajna cross-over inter-
akcija spola i dobi s koncentracijom BDNF-a (p=0.017). U muških bolesnika/ispitanika, koncentracija BNDF-a 
je značajno rasla s dobi. U ženskih bolesnica/ispitanica, korelacija između dobi i BDNF-a nije bila značajna. 
Na razini ovog uzorka, ona je bila negativna: starija dob bila je povezana s nižim koncentracijama BDNF-a u 
ženskih bolesnica/ispitanica. Koncentracije BDNF-a su se značajno razlikovale između ženskih i muških bole-
snika dobi ispod 22 godine (ukupno 7% bolesnika), i dobi iznad 65 godina (ukupno 10% bolesnika). BDNF 
bi mogao biti obećavajući biomarker shizofrenije, ali bi različite norme trebale biti predložene za bolesnike 
različite dobi i spola.
Ključne riječi: moždani neurotrofni čimbenik rasta (engl. brain derived neurotrophic factor, BDNF), shizo-
frenija, biomarker, dob, spol
